# US 2015/0147323 A1 · Modulating the alternative complement pathway

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0147323 A1
- Document ID: US20150147323A1
- Status: Published application
- Kind: A1
- Application number: 14/571,102
- Filed: 2014-12-15
- Published: 2015-05-28
- Earliest claimed: 2008-09-22
- Assignees: The Regents of the University of Colorado, a body corporate
- Applicants: The Regents of the University of Colorado, A Body Corporate
- Inventors: JOSHUA M. THURMAN; V. MICHAEL HOLERS
- Web page: https://patentgrep.com/patent/US20150147323A1

## CPC

- C07K 16/18: against material from animals or humans
- A61K 38/1709: {from mammals}
- A61K 38/177: {Receptors; Cell surface antigens; Cell surface determinants}
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 14/4721: {Lipocortins}
- C12N 9/88: Lyases (4.)
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K 2317/54: F(ab')2
- C07K 2317/55: Fab or Fab'
- C07K 2319/70: containing domain for protein-protein interaction
- C12Y 402/01002: Fumarate hydratase (4.2.1.2)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Y: ENZYMES

## Abstract

Provided herein are compositions, including pharmaceutical compositions, and methods for modulating, i.e., stimulating or inhibiting, activity of the alternative complement pathway, and methods of identifying factor H-binding proteins.

## Claims

### Claim at position 1

-20. (canceled)

### Claim 21

A method of modulating alternative complement activity in an individual, the method comprising administering to an individual in need thereof a composition comprising a fusion protein, the fusion protein comprising an anti-annexin A2 antibody or an antigen-binding fragment thereof fused to a complement inhibitor selected from the group consisting of decay-accelerating factor (DAF), factor H, membrane cofactor protein (MCP), CD59, complement receptor 1 (CR1), and mouse complement receptor 1-related gene/protein y (Crry protein), or a biologically-active fragment thereof.

### Claim 22 (depends on 21)

The method of claim 21, wherein the individual is a mammal.

### Claim 23 (depends on 22)

The method of claim 22, wherein the mammal is a human, a mouse, or a rat.

### Claim 24 (depends on 21)

The method of claim 21, wherein alternative complement activity is inhibited in the individual.

### Claim 25 (depends on 21)

The method of claim 21, wherein the administering is orally or by injection.

### Claim 26 (depends on 21)

The method of claim 21, wherein the antigen-binding fragment comprises an Fab, Fab′, or F(ab′)2 fragment.

### Claim 27 (depends on 21)

The method of claim 21, wherein the complement inhibitor is DAF.

### Claim 28 (depends on 21)

The method of claim 21, wherein the complement inhibitor is factor H.

### Claim 29 (depends on 21)

The method of claim 21, wherein the complement inhibitor is MCP.

### Claim 30 (depends on 21)

The method of claim 21, wherein the complement inhibitor is CD59.

### Claim 31 (depends on 21)

The method of claim 21, wherein the complement inhibitor is CR1.

### Claim 32 (depends on 21)

The method of claim 21, wherein the complement inhibitor is mouse Crry protein.

### Claim 33

A composition for modulating alternative complement activity, the composition comprising a fusion protein comprising an anti-annexin A2 antibody or an antigen-binding fragment thereof fused to a complement inhibitor selected from the group consisting of decay-accelerating factor (DAF), factor H, membrane cofactor protein (MCP), CD59, complement receptor 1 (CR1), and mouse complement receptor 1-related gene/protein y (Crry protein), or a biologically-active fragment thereof; and a pharmaceutically acceptable carrier.

### Claim 34 (depends on 33)

The composition of claim 33, wherein the alternative complement activity is inhibited.

### Claim 35 (depends on 33)

The composition of claim 33, wherein the antigen-binding fragment of an anti-annexin A2 antibody comprises an Fab, Fab′, or F(ab′)2 fragment.

### Claim 36 (depends on 33)

The composition of claim 33, wherein the complement inhibitor is DAF.

### Claim 37 (depends on 33)

The composition of claim 33, wherein the complement inhibitor is factor H.

### Claim 38 (depends on 33)

The composition of claim 33, wherein the complement inhibitor is MCP.

### Claim 39 (depends on 33)

The composition of claim 33, wherein the complement inhibitor is CD59.

### Claim 40 (depends on 33)

The composition of claim 33, wherein the complement inhibitor is CR1.

### Claim 41 (depends on 33)

The composition of claim 33, wherein the complement inhibitor is mouse Crry protein.
